A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers
Status:
Completed
Trial end date:
2019-02-06
Target enrollment:
Participant gender:
Summary
A phase 1, 6-sequence, 3-period, subject- and investigator blinded and sponsor-open,
crossover study in healthy volunteers to evaluate the PF-06700841 effect on QTc interval.
Each subject randomized will receive placebo, PF-06700841 200 mg and moxifloxacin (open
label) in one of the 6 sequences. Moxifloxacin is positive control to demonstrate the study
sensitivity and PF-06700841 effect on QTc will be assessed by concentration-QT analysis
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination PF-06700841